New cocktail aims to shrink brain tumors
NCT ID NCT07604987
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of five drugs (R-PMDT) in 33 people newly diagnosed with primary central nervous system lymphoma, a rare brain cancer. The goal is to see how many patients' tumors shrink or disappear after six cycles of treatment. Researchers will also track how long patients live without the cancer growing and monitor side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM (CNS) LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, 022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immune booster outsmart brain lymphoma?
- Can a Four-Pronged attack beat brain lymphoma?
- Can a daily pill keep brain lymphoma at bay after remission?
- Can a Brain-Penetrating drug tackle recurrent CNS lymphoma?
- New antibody combo aims to treat brain lymphoma
- Could a cancer drug shrink recurrent brain tumors?